USask’s VIDO announces positive Phase 1 results for COVAC-2

A volunteer being vaccinated at the CCfV trial site. (Photo: Submitted) A volunteer being vaccinated at the CCfV trial site. (Photo: Submitted)

USask’s VIDO announces positive Phase 1 results for COVAC-2

Today the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan (USask) announced positive interim results from their Phase 1 clinical trial for COVAC-2, VIDO’s COVID-19 subunit vaccine candidate.

The interim data from the study led by the Canadian Centre for Vaccinology (CCfV) demonstrates COVAC-2 is safe and well tolerated. The most common general reaction reported was a headache and the most notable local reaction was mild injection site pain. These reactions are common after most immunizations....

https://news.usask.ca/articles/research/2021/usasks-vido-announces-positive-phase-1-results-for-covac-2.php